ANI Pharmaceuticals 경영진
경영진 기준 점검 3/4
ANI Pharmaceuticals CEO는 Nikhil Lalwani, Sep2020 에 임명되었습니다 의 임기는 5.75 년입니다. 총 연간 보상은 $10.28M, 8.1% 급여 및 91.9% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $28.64M 가치에 해당하는 회사 주식의 1.65% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 4.6 년과 5.8 년입니다.
핵심 정보
Nikhil Lalwani
최고경영자
US$10.3m
총 보수
| CEO 급여 비율 | 8.15% |
| CEO 재임 기간 | 5.8yrs |
| CEO 지분 보유율 | 1.7% |
| 경영진 평균 재임 기간 | 4.6yrs |
| 이사회 평균 재임 기간 | 5.8yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • Jun 02
ANIP: Raised 2026 Outlook And Buyback Will Support Stronger Earnings Power
Analysts have trimmed their price target on ANI Pharmaceuticals by $0.75 to $109.88, reflecting updated views on fair value, a slightly higher discount rate, moderated revenue growth assumptions, a higher projected profit margin, and a lower future P/E multiple. What's in the News Q1 2026 results: Total net revenues of US$237.5 million, up 20.5% year over year, with Rare Disease products such as Cortrophin Gel and ILUVIEN as key contributors.
내러티브 업데이트 • May 13
ANIP: Higher Margin Outlook Will Support Bullish Case Over Coming Years
Analysts have maintained their $90.00 price target on ANI Pharmaceuticals, citing updated assumptions around slightly different revenue growth, a higher profit margin, and a lower future P/E as the main factors supporting the unchanged view. What's in the News Raised full year 2026 revenue guidance to a range of US$1.08b to US$1.14b, compared with prior guidance of US$1.055b to US$1.115b (company guidance).내러티브 업데이트 • Apr 24
ANIP: 2026 Revenue Guidance And New Launches Will Support Upside Potential
Analysts have kept their $90.00 price target for ANI Pharmaceuticals unchanged, citing relatively steady assumptions for revenue growth, profit margins, and future P/E as the basis for this view. What's in the News Launched Pimozide Tablets 1 mg and 2 mg, a generic version of Orap, with U.S. annual sales for the category of about US$3.1 million based on February 2026 IQVIA data (Key Developments).Seeking Alpha • Apr 10
ANI Pharmaceuticals Looks Undervalued As Cortrophin Drives Rare Disease Growth
Summary ANI Pharmaceuticals continues shifting toward rare diseases, with management projecting that this segment will represent 60% of its 2026 revenues. However, their generics remain a reliable cash engine. These products grew 28% in 2025 and reached $384 million in revenues. This way, ANIP has been able to fund its expansion into rare diseases, with Cortrophin as its flagship asset in this category. Cortrophin has an extremely promising multi-indication potential, as well as plans for a prefilled syringe launch supported by another Phase 4 gout study. On balance, I think ANIP’s valuation seems exceedingly cheap relative to its stable revenue growth and positive cash flows, which is why I rate the stock a “Buy”. Read the full article on Seeking Alpha내러티브 업데이트 • Apr 08
ANIP: 2026 Revenue Guidance Will Test Confidence In Margin Assumptions
Analysts lifted their price target on ANI Pharmaceuticals by $9, reflecting updated expectations around revenue growth, profit margin, and future P/E assumptions highlighted in recent Street research. Analyst Commentary While the updated target reflects renewed confidence in revenue and margin assumptions, bearish analysts are still flagging several areas where expectations may be running ahead of what the company can reasonably deliver.내러티브 업데이트 • Mar 25
ANIP: Higher 2026 Guidance And Margin Outlook Will Support Stronger Earnings Power
Analysts have raised their price target on ANI Pharmaceuticals by $9 to $110.63, citing updated expectations for revenue growth, profit margins, and a lower future P/E assumption. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as better aligned with updated expectations for revenue and margin performance, which they factor into their cash flow and earnings models.내러티브 업데이트 • Mar 11
ANIP: Higher 2026 Guidance Will Test Assumed Margin Expansion
Analysts have lifted their price target on ANI Pharmaceuticals by $9, citing updated assumptions for revenue growth, profit margins, and a revised future P/E multiple that together reshape their view of the stock's long term earnings power. Analyst Commentary While the higher price target reflects updated assumptions, bearish analysts are also flagging several risks that could limit upside if execution or market conditions do not line up with those assumptions.내러티브 업데이트 • Feb 24
ANIP: Higher 2026 Revenue Guidance Will Support Richer Forward P/E Multiple
Analysts have lifted their price target on ANI Pharmaceuticals by $9, reflecting updated assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Bullish Takeaways Bullish analysts view the US$9 price target increase as a sign that updated revenue assumptions support a higher valuation multiple on forward earnings.내러티브 업데이트 • Feb 10
ANIP: Higher 2026 Revenue Outlook And Refined P/E Framework Will Support Upside
Analysts have raised their price target on ANI Pharmaceuticals by about $1 to $110.50, citing updated views on revenue growth, profit margins, discount rate, and future P/E assumptions reflected in recent research. Analyst Commentary Bullish Takeaways Bullish analysts see the higher US$110.50 target as better aligned with updated assumptions on revenue and margins, suggesting the stock now reflects their latest fundamental work more closely.내러티브 업데이트 • Jan 26
ANIP: Future Outlook Will Balance Higher Guidance Expectations And Execution Risks
Analysts have raised their price target on ANI Pharmaceuticals by $9, citing updated expectations for revenue growth, profit margins, and a slightly lower future P/E as key drivers of their revised view. Analyst Commentary While the higher price target signals some confidence around updated revenue and margin expectations, bearish analysts are still flagging areas where the risk and reward profile may feel less attractive for new money.내러티브 업데이트 • Jan 12
ANIP: Raised Revenue Outlook And Pipeline Update Will Support Further Upside
Narrative Update on ANI Pharmaceuticals Analysts have trimmed their price target on ANI Pharmaceuticals to about $109.25 from roughly $109.88, citing updated assumptions around slightly higher revenue growth expectations, a modestly lower profit margin outlook, and a small adjustment in the forward P/E multiple. What’s in the News ANI Pharmaceuticals raised its full year 2025 net revenue guidance to a range of US$854 million to US$873 million, compared with prior guidance of US$818 million to US$843 million (Key Developments).내러티브 업데이트 • Dec 26
ANIP: Future Outlook Will Balance Corticotropin Momentum And Concentration Risks
Analysts have raised their price target on ANI Pharmaceuticals to $90 from $77, citing continued momentum from Cortrophin Gel, record Q2 sales of $82M, and a 20% full year guidance increase that supports expectations for sustained growth. Analyst Commentary Bearish analysts acknowledge that the higher $90 price target reflects recent strength, but they emphasize that the rating remains at Hold, signaling caution around near term upside.내러티브 업데이트 • Dec 12
ANIP: Future Outlook Balances Corticotropin Market Expansion And Competitive Uncertainties
Analysts have lifted their fair value estimate for ANI Pharmaceuticals to $90 from $77 per share as they factor in stronger than expected Cortrophin Gel momentum, higher sales visibility, and an expanding addressable market, despite slightly more conservative growth and margin assumptions. Analyst Commentary Recent Street research reflects a growing divide between optimistic expectations for Cortrophin Gel and a more cautious stance from bearish analysts who question the durability of current momentum and the stock's valuation profile.내러티브 업데이트 • Nov 26
ANIP: Continued Momentum Will Drive Upside as Market Opportunities Expand
Analysts have raised their price targets for ANI Pharmaceuticals, with increases ranging from $13 to $28 per share. They cite strong Cortrophin Gel sales momentum, expanded market opportunities, and resilient fundamentals as key factors driving the company’s continued growth outlook.내러티브 업데이트 • Nov 10
ANIP: Sustained Revenue Expansion Will Drive Momentum Amid Increasing Market Opportunities
Analysts have increased their average price target for ANI Pharmaceuticals from $105 to approximately $109.88, citing robust Cortrophin Gel performance, expanded market opportunities, and a strengthened revenue outlook. Analyst Commentary Industry analysts are closely monitoring ANI Pharmaceuticals following a series of price target increases.내러티브 업데이트 • Sep 25
Expanding ACTH Potential And Rare Disease Markets Will Evolve
ANI Pharmaceuticals’ price target was raised to $105.00 as analysts cite robust Cortrophin Gel prescription trends, a significantly expanded addressable market, and outstanding Q2 revenue growth. Analyst Commentary Bullish analysts highlight that Cortrophin Gel prescription data is consistently surpassing forecasts, indicating stronger-than-expected demand.내러티브 업데이트 • Aug 10
Expanding ACTH Potential And Rare Disease Markets Will Evolve
Despite a meaningful reduction in consensus revenue growth forecasts, ANI Pharmaceuticals’ future P/E multiple has declined, improving perceived value and contributing to an upward revision of the consensus analyst price target from $81.38 to $85.75. What's in the News ANI Pharmaceuticals raised 2025 earnings guidance to $818–$843 million from prior $768–$793 million.분석 기사 • Aug 10
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Surges 25% Yet Its Low P/S Is No Reason For Excitement
NasdaqGM:ANIP 1 Year Share Price vs Fair Value Explore ANI Pharmaceuticals's Fair Values from the Community and select...분석 기사 • Jun 21
Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • May 16
We Think Shareholders Will Probably Be Generous With ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) CEO Compensation
Key Insights ANI Pharmaceuticals' Annual General Meeting to take place on 22nd of May Total pay for CEO Nikhil Lalwani...분석 기사 • Mar 28
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Fly 25% But Investors Aren't Buying For Growth
ANI Pharmaceuticals, Inc. ( NASDAQ:ANIP ) shareholders have had their patience rewarded with a 25% share price jump in...분석 기사 • Feb 25
Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Feb 11
ANI Pharmaceuticals: More Than Just A Generics Company
Summary ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, and contract manufacturing. Despite cash burn concerns, ANI's revenue growth, strategic moves, and overlooked royalty streams indicate long-term value creation. ANI's rare disease asset, Purified Cortrophin Gel, and generics pipeline, including Prucalopride, position it for significant revenue growth and market re-rating. The company's debt restructuring and diversified revenue streams enhance financial stability, making it a potential buyout target in the specialty pharma sector. Read the full article on Seeking Alpha분석 기사 • Dec 18
ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Prospects Need A Boost To Lift Shares
You may think that with a price-to-sales (or "P/S") ratio of 2x ANI Pharmaceuticals, Inc. ( NASDAQ:ANIP ) is a stock...분석 기사 • Nov 09
Here's Why ANI Pharmaceuticals (NASDAQ:ANIP) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Seeking Alpha • Nov 02
ANI Pharmaceuticals Is Acting Like It Is Being Acquired
Summary Several actions or omissions by ANIP is consistent with them being acquired and being restricted in what they can disclose. Offer could exceed $8 billion plus sales based CVRs. Offer likely contingent on FDA approval of NDA filed in Q3 2023 for undisclosed drug filed by ANIP but application appears to be financed by undisclosed partner. Read the full article on Seeking AlphaSeeking Alpha • Oct 11
ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market
Summary Today, we revisit small biopharma ANI Pharmaceuticals, as it is a GARP stock trading near technical support, with solid growth prospects. The company recently acquired Alimera Sciences for $380 million, boosting its rare disease segment with a couple of durable ophthalmology products. Analyst firms are generally bullish on the company's prospects and the stock trades at 12 times trailing earnings, despite revenue growth in the high teens. An analysis of ANIP follows in the paragraphs below. Read the full article on Seeking Alpha
새로운 내러티브 • Sep 15
Purified Cortrophin Gel And Strategic Acquisitions Propel Robust Revenue Surge In Rare Disease Sector
Accelerating demand for their lead Rare Disease asset and growth in generics, along with expanding sales efforts, are expected to significantly boost revenues.분석 기사 • Sep 10
There's No Escaping ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Muted Revenues
ANI Pharmaceuticals, Inc.'s ( NASDAQ:ANIP ) price-to-sales (or "P/S") ratio of 2.2x might make it look like a buy right...분석 기사 • Aug 14
ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem
ANI Pharmaceuticals, Inc.'s ( NASDAQ:ANIP ) robust earnings report didn't manage to move the market for its stock. Our...분석 기사 • Aug 08
Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Aug 02
ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028
Summary ANIP has three 505(b)(2) NDA submissions under FDA review, including oral liquid terazosin, female testosterone drug, and oral liquid hydrochlorothiazide. Potential peak sales for Tezruly and hydrochlorothiazide in the US could exceed $500 million, while the female testosterone drug could generate $290 million in royalties. ANIP's revenue could reach $1.41 billion in sales and $290 million in royalties by 2028, with significant growth potential. Read the full article on Seeking Alpha분석 기사 • Jun 10
Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price
There wouldn't be many who think ANI Pharmaceuticals, Inc.'s ( NASDAQ:ANIP ) price-to-sales (or "P/S") ratio of 2.5x is...Seeking Alpha • Jun 10
ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked
Summary ANIP's potential royalty revenue from two upcoming drug applications could generate $415 million annually, not reflected in the current share price. ANI Pharmaceuticals' legal action against CG Oncology could result in royalties for Cretostimogene, potentially adding $125 million per year. The Company's female testosterone drug could generate royalties of $290 million per year, with potential for additional indications and international sales. Read the full article on Seeking AlphaCEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$84m |
| Dec 31 2025 | US$10m | US$837k | US$70m |
| Sep 30 2025 | n/a | n/a | US$34m |
| Jun 30 2025 | n/a | n/a | -US$14m |
| Mar 31 2025 | n/a | n/a | -US$22m |
| Dec 31 2024 | US$9m | US$795k | -US$20m |
| Sep 30 2024 | n/a | n/a | -US$9m |
| Jun 30 2024 | n/a | n/a | US$24m |
| Mar 31 2024 | n/a | n/a | US$31m |
| Dec 31 2023 | US$8m | US$764k | US$15m |
| Sep 30 2023 | n/a | n/a | US$10m |
| Jun 30 2023 | n/a | n/a | -US$8m |
| Mar 31 2023 | n/a | n/a | -US$28m |
| Dec 31 2022 | US$5m | US$737k | -US$50m |
| Sep 30 2022 | n/a | n/a | -US$69m |
| Jun 30 2022 | n/a | n/a | -US$65m |
| Mar 31 2022 | n/a | n/a | -US$63m |
| Dec 31 2021 | US$7m | US$715k | -US$43m |
| Sep 30 2021 | n/a | n/a | -US$22m |
| Jun 30 2021 | n/a | n/a | -US$17m |
| Mar 31 2021 | n/a | n/a | -US$15m |
| Dec 31 2020 | US$4m | US$199k | -US$23m |
보상 대 시장: Nikhil의 총 보수(USD10.28M)는 US 시장에서 비슷한 규모 기업의 평균(USD5.25M)보다 높습니다.
보상과 수익: Nikhil의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Nikhil Lalwani (48 yo)
5.8yrs
재임 기간
US$10,278,620
보수
Mr. Nikhil Lalwani is President, CEO & Director of ANI Pharmaceuticals, Inc. from September 08, 2020. Mr. Lalwani joined the ANI Pharmaceuticals, Inc. on September 08, 2020. Mr. Lalwani served as a Directo...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| President | 5.8yrs | US$10.28m | 1.65% $ 28.6m | |
| Senior VP of Finance & CFO | 10.1yrs | US$3.25m | 0.85% $ 14.8m | |
| Senior VP | 3.9yrs | US$2.32m | 0.37% $ 6.4m | |
| Senior Vp & Head of Rare Disease | 5.3yrs | US$3.40m | 0.29% $ 5.1m | |
| Senior Vice President of Generics | 5.3yrs | US$2.31m | 0.37% $ 6.4m | |
| Head of R&D | 4.6yrs | 데이터 없음 | 0.39% $ 6.8m | |
| Chief Compliance Officer & Head of Legal of Rare Disease | 4.3yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Corporate Development & Strategy | 4.6yrs | US$1.90m | 1.1% $ 19.1m | |
| Senior VP & Chief Human Resources Officer | 3.8yrs | 데이터 없음 | 0.24% $ 4.3m | |
| Chief Medical Officer | 4.3yrs | 데이터 없음 | 데이터 없음 | |
| Senior VP & Head of Established Brands | 4.6yrs | 데이터 없음 | 0.18% $ 3.1m |
4.6yrs
평균 재임 기간
53yo
평균 나이
경험이 풍부한 관리: ANIP의 경영진은 경험이 있음으로 간주됩니다(평균 재임 4.6 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| President | 5.8yrs | US$10.28m | 1.65% $ 28.6m | |
| Head of R&D | 4.6yrs | 데이터 없음 | 0.39% $ 6.8m | |
| Independent Director | 5.8yrs | US$327.57k | 0.11% $ 1.9m | |
| Independent Chairman of the Board | 8.1yrs | US$343.09k | 0.17% $ 3.0m | |
| Independent Director | 5.8yrs | US$331.33k | 0.11% $ 1.9m | |
| Independent Director | 4.3yrs | US$332.57k | 0.12% $ 2.1m | |
| Independent Director | 2.8yrs | US$327.57k | 0.032% $ 561.8k |
5.8yrs
평균 재임 기간
62yo
평균 나이
경험이 풍부한 이사회: ANIP의 이사회는 경험이 있음으로 간주됩니다(평균 재임 5.8 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/06/11 07:24 |
| 종가 | 2026/06/11 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
ANI Pharmaceuticals, Inc.는 16명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Glen Santangelo | Barclays |
| Dewey Steadman | Canaccord Genuity |
| Timothy Chiang | Capital One Securities, Inc. |